Logo image of AMGN

AMGEN INC (AMGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AMGN - US0311621009 - Common Stock

324.3 USD
-1.24 (-0.38%)
Last: 1/13/2026, 8:00:00 PM
322.62 USD
-1.68 (-0.52%)
Pre-Market: 1/14/2026, 6:18:28 AM
Fundamental Rating

5

Taking everything into account, AMGN scores 5 out of 10 in our fundamental rating. AMGN was compared to 528 industry peers in the Biotechnology industry. While AMGN has a great profitability rating, there are quite some concerns on its financial health. AMGN has a decent growth rate and is not valued too expensively. Finally AMGN also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • AMGN had positive earnings in the past year.
  • AMGN had a positive operating cash flow in the past year.
  • In the past 5 years AMGN has always been profitable.
  • AMGN had a positive operating cash flow in each of the past 5 years.
AMGN Yearly Net Income VS EBIT VS OCF VS FCFAMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

  • With an excellent Return On Assets value of 7.77%, AMGN belongs to the best of the industry, outperforming 92.99% of the companies in the same industry.
  • AMGN has a better Return On Equity (72.82%) than 99.05% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.39%, AMGN belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for AMGN is significantly below the industry average of 18.28%.
  • The last Return On Invested Capital (15.39%) for AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.77%
ROE 72.82%
ROIC 15.39%
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
AMGN Yearly ROA, ROE, ROICAMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 50 100 150

1.3 Margins

  • AMGN has a better Profit Margin (19.47%) than 93.18% of its industry peers.
  • AMGN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of AMGN (33.57%) is better than 97.16% of its industry peers.
  • AMGN's Operating Margin has declined in the last couple of years.
  • The Gross Margin of AMGN (72.06%) is better than 82.58% of its industry peers.
  • AMGN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.57%
PM (TTM) 19.47%
GM 72.06%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
AMGN Yearly Profit, Operating, Gross MarginsAMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

3

2. Health

2.1 Basic Checks

  • AMGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for AMGN has been increased compared to 1 year ago.
  • Compared to 5 years ago, AMGN has less shares outstanding
  • The debt/assets ratio for AMGN has been reduced compared to a year ago.
AMGN Yearly Shares OutstandingAMGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
AMGN Yearly Total Debt VS Total AssetsAMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • The Debt to FCF ratio of AMGN is 4.28, which is a neutral value as it means it would take AMGN, 4.28 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 4.28, AMGN belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
  • A Debt/Equity ratio of 5.45 is on the high side and indicates that AMGN has dependencies on debt financing.
  • AMGN has a worse Debt to Equity ratio (5.45) than 80.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.45
Debt/FCF 4.28
Altman-Z N/A
ROIC/WACC1.79
WACC8.58%
AMGN Yearly LT Debt VS Equity VS FCFAMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.28 indicates that AMGN should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.28, AMGN is doing worse than 83.14% of the companies in the same industry.
  • AMGN has a Quick Ratio of 1.28. This is a bad value and indicates that AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AMGN's Quick ratio of 0.99 is on the low side compared to the rest of the industry. AMGN is outperformed by 85.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.99
AMGN Yearly Current Assets VS Current LiabilitesAMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.79% over the past year.
  • AMGN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.97% yearly.
  • AMGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.56%.
  • AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.43% yearly.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.77% on average over the next years.
  • The Revenue is expected to grow by 3.63% on average over the next years.
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMGN Yearly Revenue VS EstimatesAMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
AMGN Yearly EPS VS EstimatesAMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

6

4. Valuation

4.1 Price/Earnings Ratio

  • AMGN is valuated correctly with a Price/Earnings ratio of 14.83.
  • AMGN's Price/Earnings ratio is rather cheap when compared to the industry. AMGN is cheaper than 96.21% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of AMGN to the average of the S&P500 Index (27.30), we can say AMGN is valued slightly cheaper.
  • The Price/Forward Earnings ratio is 14.48, which indicates a correct valuation of AMGN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 96.02% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. AMGN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.83
Fwd PE 14.48
AMGN Price Earnings VS Forward Price EarningsAMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMGN is valued cheaper than 95.83% of the companies in the same industry.
  • 97.16% of the companies in the same industry are more expensive than AMGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.69
EV/EBITDA 12.44
AMGN Per share dataAMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • AMGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AMGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.57
PEG (5Y)2.48
EPS Next 2Y6.31%
EPS Next 3Y5.32%

8

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.05%, AMGN has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.26, AMGN pays a better dividend. On top of this AMGN pays more dividend than 98.86% of the companies listed in the same industry.
  • AMGN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.92.
Industry RankSector Rank
Dividend Yield 3.05%

5.2 History

  • The dividend of AMGN is nicely growing with an annual growth rate of 9.41%!
  • AMGN has paid a dividend for at least 10 years, which is a reliable track record.
  • AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
AMGN Yearly Dividends per shareAMGN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6 8

5.3 Sustainability

  • 17.20% of the earnings are spent on dividend by AMGN. This is a low number and sustainable payout ratio.
  • The dividend of AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
AMGN Yearly Income VS Free CF VS DividendAMGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B
AMGN Dividend Payout.AMGN Dividend Payout, showing the Payout Ratio.AMGN Dividend Payout.PayoutRetained Earnings

AMGEN INC

NASDAQ:AMGN (1/13/2026, 8:00:00 PM)

Premarket: 322.62 -1.68 (-0.52%)

324.3

-1.24 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-03
Inst Owners83.87%
Inst Owner Change-0.04%
Ins Owners0.06%
Ins Owner Change-0.77%
Market Cap174.63B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72.2
Price Target334.67 (3.2%)
Short Float %2.63%
Short Ratio5
Dividend
Industry RankSector Rank
Dividend Yield 3.05%
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date02-13
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)0.48%
PT rev (3m)4.6%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)-7.7%
EPS NY rev (1m)0.02%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)1.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.75%
Valuation
Industry RankSector Rank
PE 14.83
Fwd PE 14.48
P/S 4.85
P/FCF 13.69
P/OCF 13.3
P/B 18.15
P/tB N/A
EV/EBITDA 12.44
EPS(TTM)21.87
EY6.74%
EPS(NY)22.4
Fwd EY6.91%
FCF(TTM)23.69
FCFY7.3%
OCF(TTM)24.38
OCFY7.52%
SpS66.8
BVpS17.86
TBVpS-59.79
PEG (NY)1.57
PEG (5Y)2.48
Graham Number93.76
Profitability
Industry RankSector Rank
ROA 7.77%
ROE 72.82%
ROCE 17.67%
ROIC 15.39%
ROICexc 17.86%
ROICexgc 61.56%
OM 33.57%
PM (TTM) 19.47%
GM 72.06%
FCFM 35.46%
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 5.45
Debt/FCF 4.28
Debt/EBITDA 2.97
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 74.3%
Profit Quality 182.08%
Current Ratio 1.28
Quick Ratio 0.99
Altman-Z N/A
F-Score7
WACC8.58%
ROIC/WACC1.79
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year42.71%
EBIT Next 3Y11.36%
EBIT Next 5Y7.69%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%

AMGEN INC / AMGN FAQ

Can you provide the ChartMill fundamental rating for AMGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to AMGN.


What is the valuation status of AMGEN INC (AMGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.


What is the profitability of AMGN stock?

AMGEN INC (AMGN) has a profitability rating of 7 / 10.


How financially healthy is AMGEN INC?

The financial health rating of AMGEN INC (AMGN) is 3 / 10.


What is the earnings growth outlook for AMGEN INC?

The Earnings per Share (EPS) of AMGEN INC (AMGN) is expected to grow by 9.46% in the next year.